Key result
BuShenKangShuai tablet alleviated hepatic steatosis, decreased blood lipids, and increased serum adiponectin in ApoE-/- mice by improving liver adiponectin resistance.
Why the study?
To explore whether BuShenKangShuai tablet administration can alleviate hepatic steatosis via improving liver adiponectin resistance in ApoE-/- mice.
Does BuShenKangShuai tablet alleviate hepatic steatosis in ApoE-/- mice?
Does BuShenKangShuai tablet alleviate hepatic steatosis in ApoE-/- mice?
In a preclinical model, BuShenKangShuai tablet alleviated hepatic steatosis and improved dyslipidemia by modulating liver adiponectin resistance and inflammatory signaling.
BuShenKangShuai tablet (BSKS) is a Chinese herbal compound, which has been used to treat nonalcoholic fatty liver disease and cardiovascular diseases in clinic for over four decades. This study intends to explore whether BSKS administration can alleviates hepatic steatosis via improving liver adiponectin resistance in ApoE-/- mice. ApoE-/- mice were fed with western-type diet for 6 weeks and then were administrated with BSKS or atorvastatin for 6 weeks by gavage, and then blood and liver were collected for analysis. The results showed that BSKS attenuated hepatic steatosis, decreased blood lipids, and increased the serum level of adiponectin. We also found that adiponectin resistance in the liver was improved by BSKS, while the expression of TLR4 and NF-κB p65 was inhibited, followed by the suppression of proinflammatory mediators of TNF-α. Our data provided evidence that BSKS was able to alleviate hepatic steatosis in vivo. The underlying mechanism of BSKS was focused on improving liver adiponectin resistance, thereby regulating dyslipidemia and inhibiting inflammatory signaling pathway.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2019) studied Hepatic steatosis. BuShenKangShuai tablet (BSKS) vs. atorvastatin was evaluated on Hepatic steatosis, blood lipids, and serum adiponectin levels. BuShenKangShuai tablet alleviated hepatic steatosis, decreased blood lipids, and increased serum adiponectin in ApoE-/- mice by improving liver adiponectin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: